"目录号: HY-13662B
Membrane Transporter/Ion Channel-
(R)-Lansoprazole是质子泵抑制剂，能抑制胃酸生成。
Proton Pump
相关产品
TAK-438-Omeprazole-Pantoprazole sodium-Lansoprazole-Zinc Pyrithione-AZD0865-Ilaprazole-Esomeprazole Magnesium trihydrate-Bamaquimast-Rabeprazole sodium-Soraprazan-Chebulinic acid-Picoprazole-SKF96067-Tenatoprazole sodium-
生物活性
Description
(R)-Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid.Target: Proton PumpLansoprazole sodium is sodium salt form of lansoprazole, lansoprazole, a substituted benzimidizole proton pump inhibitor, on pharmacokinetics and metabolism of theophylline has been studied in healthy adults given oral lansoprazole 30 mg once daily for 11 days. On Days 4 and 11 of 300 mg aminophylline was simultaneously administered orally and blood samples for theophylline analysis were taken over 24 h [1]. Patients in the lansoprazole group were significantly less likely to have a recurrence of ulcer complications than patients in the placebo group (P=0.008). There was no significant difference in mortality between the two groups [2]. lansoprazole (AG-1749) and omeprazole, were found to have significant activities against this organism. The activity of lansoprazole was comparable to that of bismuth citrate, with MICs ranging from 3.13 to 12.5 micrograms/ml, and fourfold more potent than that of omeprazole [3]. �
Clinical Trial
NCT01642602
Takeda
Gastroesophageal Reflux Disease
July 2012
Phase 2
NCT02096458
Takeda
Gastroesophageal Reflux Disease-Erosive Esophagitis-Heartburn
February 2014
Phase 1
NCT02064907
Takeda
Bioavailability
February 2014
Phase 1
NCT02442752
Takeda
Pediatric Gastroesophageal Reflux Disease
February 2016
Phase 1
NCT02162758
Takeda
Barrett's Esophagus
July 2014
Phase 2
NCT02616302
Takeda
Gastroesophageal Reflux
November 2015
Phase 2
NCT01317472
Indiana University
Laryngopharyngeal Reflux
March 2011
NCT03087162
Ramathibodi Hospital
H Pylori Eradication
January 1, 2017
Phase 4
NCT02351960
Takeda
Gastroesophageal Reflux Disease
March 2015
Phase 4
NCT01642615
Takeda
Gastroesophageal Reflux Disease-Erosive Esophagitis
July 2012
Phase 2
NCT02615184
Takeda
Erosive Esophagitis
November 2015
Phase 2
NCT00255190
Takeda
Gastroesophageal Reflux Disease
January 2006
Phase 3
NCT02541786
Kaohsiung Medical University
Helicobacter Pylori Infection
January 2015
Phase 4
NCT00847210
Takeda
Gastroesophageal Reflux
May 2009
Phase 1
NCT02873689
Takeda
Heartburn-Gastroesophageal Reflux Disease
December 31, 2016
Phase 3
NCT01328652
Advanced Center for Specialty Care-Takeda
Laryngopharyngeal Reflux-Hypertrophy of Lingual Tonsil
June 2011
Phase 4
NCT03079050
American University of Beirut Medical Center-Takeda
GERD-Proton Pump Inhibitor
February 27, 2017
Phase 4
NCT03128736
Kaohsiung Medical University Chung-Ho Memorial Hospital
Gastroesophageal Reflux Disease
April 1, 2014
Phase 4
NCT00847808
Takeda
Gastroesophageal Reflux
February 2009
Phase 3
NCT00255151
Takeda
Esophagitis, Reflux-Esophagitis, Peptic
January 2006
Phase 3
NCT00255164
Takeda
Esophagitis, Reflux-Esophagitis, Peptic
January 2006
Phase 3
NCT00251758
Takeda
Gastroesophageal Reflux Disease
December 2005
Phase 3
NCT00251745
Takeda
Gastroesophageal Reflux Disease
December 2005
Phase 3
NCT00321984
Takeda
Gastroesophageal Reflux Disease
June 2006
Phase 3
NCT01045096
Takeda
Gastroesophageal Reflux
March 2010
Phase 1
NCT01216293
Takeda
Homeostasis-Bone and Bones
January 2011
Phase 1
NCT02873702
Takeda
Erosive Esophagitis
December 31, 2016
Phase 3
NCT03131895
Takeda
Healthy Volunteers
April 24, 2017
Phase 1
NCT03120273
First Affiliated Hospital of Zhejiang University-Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Effect of Drugs-Safety Issues
May 5, 2017
Phase 1
NCT00251693
Takeda
Esophagitis, Reflux-Esophagitis, Peptic
December 2005
Phase 3
NCT00251719
Takeda
Esophagitis, Reflux-Esophagitis, Peptic
December 2005
Phase 3
NCT00321737
Takeda
Esophagitis, Reflux-Esophagitis, Peptic
May 2006
Phase 3
NCT02759393
National Cheng-Kung University Hospital
Gastroesophageal Reflux Disease
October 2015
Phase 4
NCT00627016
Takeda
Gastroesophageal Reflux
March 2008
Phase 3
NCT01149395
University of North Carolina, Chapel Hill
Heartburn-Gastroesophageal Reflux Disease
June 2010
Phase 1
NCT03011125
First Affiliated Hospital of Zhejiang University-Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Safety Issues
January 2017
Phase 1
NCT00942175
Takeda
Healthy
December 2009
Phase 1
NCT03202537
Northwestern University-Washington University School of Medicine-Vanderbilt University
Gastro Esophageal Reflux
July 1, 2017
Early Phase 1
NCT01328392
University of Washington-Takeda Pharmaceuticals North America, Inc.
Laryngo-pharyngeal Reflux
May 2011
NCT01093755
Mayo Clinic
Inflammation-Barrett's Esophagus
March 2010
Phase 4
NCT01479231
Mayo Clinic
Gastroesophageal Reflux Disease-Eosinophilic Esophagitis-Dysphagia
March 2012
Phase 1-Phase 2
NCT02490449
Soonchunhyang University Hospital
Nonerosive Reflux Disease
December 2014
NCT03043521
CJ HealthCare Corporation
Healthy
May 13, 2015
Phase 1
NCT00928161
M.D. Anderson Cancer Center-TAP Pharmaceutical Products Inc.
Head and Neck Cancer-Oropharyngeal Cancer-Gastroesophageal Reflux Disease
November 2012
View MoreCollapse
References
[1].Kokufu, T., et al., Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol, 1995. 48(5): p. 391-5.
[2].Lai, K.C., et al., Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med, 2002. 346(26): p. 2033-8.
[3].Iwahi, T., et al., Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother, 1991. 35(3): p. 490-6.